Targeted radiotherapy with radiolabeled somatostatin analogs

Publication

Targeted radiotherapy with radiolabeled somatostatin analogs

Journal Paper/Review - Mar 1, 2011

Nicolas Guillaume, Giovacchini Giampiero, Müller-Brand Jan, Forrer Flavio

Citation

Nicolas G, Giovacchini G, Müller-Brand J, Forrer F. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin North Am 2011; 40:187-204, ix-x.

Type

Journal Paper/Review (English)

Journal

Endocrinol Metab Clin North Am 2011; 40

Publication Date

Mar 1, 2011

Issn Electronic

1558-4410

Pages

187-204, ix-x

Brief description/objective

Targeted radiopeptide therapy with (90)Yttrium- or (177)Lutetium-labeled somatostatin analogs has been proven to improve significantly quality of life and survival in patients suffering from metastatic or unresectable neuroendocrine tumors (NETs). Roughly 25% of patients achieve partial remission; progression-free survival is estimated to be 30 to 40 months. A wide range of protocols using different somatostatin analogs, isotopes, injected activity per cycle of administration, and number of cycles are reported. More patient-based therapy protocols are under development, taking into consideration the complexity of NET cell biology, dosimetric issues, and the availability of different radiolabeled analogs. This article reviews the effectiveness and safety of the different protocols and discusses several clinical algorithms used in an attempt to optimize targeted radiopeptide therapy.